Leerink Partnrs Has Bullish Estimate for TMO FY2025 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Analysts at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for Thermo Fisher Scientific in a research report issued on Wednesday, October 22nd. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $22.70 per share for the year, up from their previous estimate of $22.47. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific’s Q4 2025 earnings at $6.40 EPS, Q2 2026 earnings at $6.00 EPS and Q4 2026 earnings at $6.86 EPS.

Several other research analysts also recently commented on the company. Wells Fargo & Company lifted their price objective on Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Robert W. Baird boosted their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. TD Cowen boosted their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. HSBC restated a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, William Blair started coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating on the stock. Nineteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $595.75.

Thermo Fisher Scientific Stock Down 1.4%

TMO opened at $564.49 on Monday. The company has a market cap of $213.16 billion, a P/E ratio of 32.61, a P/E/G ratio of 3.35 and a beta of 0.77. The business’s 50-day moving average price is $505.57 and its 200-day moving average price is $454.34. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific has a 12 month low of $385.46 and a 12 month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds have recently made changes to their positions in TMO. Norges Bank purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $2,264,615,000. Soundwatch Capital LLC purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $807,713,000. Flossbach Von Storch SE raised its holdings in Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock worth $1,105,698,000 after acquiring an additional 1,314,182 shares during the last quarter. Nuveen LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $532,360,000. Finally, EdgePoint Investment Group Inc. raised its holdings in Thermo Fisher Scientific by 282.5% in the 2nd quarter. EdgePoint Investment Group Inc. now owns 1,323,065 shares of the medical research company’s stock worth $536,450,000 after acquiring an additional 977,127 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,666 shares of company stock worth $13,990,971. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.